Cargando…
Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as im...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124332/ https://www.ncbi.nlm.nih.gov/pubmed/33925214 http://dx.doi.org/10.3390/jcm10091919 |
_version_ | 1783693173680242688 |
---|---|
author | Olivares-Hernández, Alejandro Figuero-Pérez, Luis Terán-Brage, Eduardo López-Gutiérrez, Álvaro Velasco, Álvaro Tamayo Sarmiento, Rogelio González Cruz-Hernández, Juan Jesús Miramontes-González, José Pablo |
author_facet | Olivares-Hernández, Alejandro Figuero-Pérez, Luis Terán-Brage, Eduardo López-Gutiérrez, Álvaro Velasco, Álvaro Tamayo Sarmiento, Rogelio González Cruz-Hernández, Juan Jesús Miramontes-González, José Pablo |
author_sort | Olivares-Hernández, Alejandro |
collection | PubMed |
description | Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice. |
format | Online Article Text |
id | pubmed-8124332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81243322021-05-17 Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies Olivares-Hernández, Alejandro Figuero-Pérez, Luis Terán-Brage, Eduardo López-Gutiérrez, Álvaro Velasco, Álvaro Tamayo Sarmiento, Rogelio González Cruz-Hernández, Juan Jesús Miramontes-González, José Pablo J Clin Med Review Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice. MDPI 2021-04-28 /pmc/articles/PMC8124332/ /pubmed/33925214 http://dx.doi.org/10.3390/jcm10091919 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Olivares-Hernández, Alejandro Figuero-Pérez, Luis Terán-Brage, Eduardo López-Gutiérrez, Álvaro Velasco, Álvaro Tamayo Sarmiento, Rogelio González Cruz-Hernández, Juan Jesús Miramontes-González, José Pablo Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies |
title | Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies |
title_full | Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies |
title_fullStr | Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies |
title_full_unstemmed | Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies |
title_short | Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies |
title_sort | resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: a new therapeutic targeting of haematological malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124332/ https://www.ncbi.nlm.nih.gov/pubmed/33925214 http://dx.doi.org/10.3390/jcm10091919 |
work_keys_str_mv | AT olivareshernandezalejandro resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies AT figueroperezluis resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies AT teranbrageeduardo resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies AT lopezgutierrezalvaro resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies AT velascoalvarotamayo resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies AT sarmientorogeliogonzalez resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies AT cruzhernandezjuanjesus resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies AT miramontesgonzalezjosepablo resistancetoimmunecheckpointinhibitorssecondarytomyeloidderivedsuppressorcellsanewtherapeutictargetingofhaematologicalmalignancies |